Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

Key Takeaway: Acadia Pharmaceuticals secured an exclusive distribution deal with KYORIN Pharmaceutical for DAYBUE STIX in Japan. KYORIN will lead commercialization and regulatory activities for the Rett syndrome treatment. This agreement expands Acadia's market reach for its trofinetide product in the Japanese healthcare sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exclusive distribution agreement with KYORIN Pharmaceutical.
  • DAYBUE STIX to be commercialized for Rett syndrome in Japan.
  • KYORIN will handle regulatory activities for the product.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
6.4%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad

Frequently Asked Questions

What is DAYBUE STIX used for?

DAYBUE STIX is used for the treatment of Rett syndrome.

Who will commercialize DAYBUE STIX in Japan?

KYORIN Pharmaceutical will lead the commercialization in Japan.

What does the agreement involve?

The agreement includes commercialization and regulatory activities.

When was the agreement announced?

The agreement was announced today by Acadia Pharmaceuticals.

Last updated: Nov 16, 2026